HBAN vs TBPH · P/E 13, rev $1.56B vs P/E 7.5, rev $38.4M
Huntington Bancshares Incorporated (HBAN) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
Huntington Bancshares Incorporated (HBAN) is a banks - regional company listed on US.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported HBAN revenue for 2025-12-31 was $1.56B. Net income was $2.21B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
Latest reported TBPH revenue for 2026-06-30 was $38.4M. Net income was -$10.8M. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
HBAN currently screens at market cap $25.55B and trailing P/E 13.5. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the HBAN and TBPH stock pages for the full models.
Not investment advice.